United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - tablet - 25 mg - major depressive disorder –sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. the efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (seeclinical trials under clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the antidepressant action of sertraline hydr

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - doxepin hydrochloride (unii: 3u9a0fe9n5) (doxepin - unii:5asj6huz7d) - capsule - 10 mg - doxepin hydrochloride capsules are recommended for the treatment of: - psychoneurotic patients with depression and/or anxiety. psychoneurotic patients with depression and/or anxiety. - depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). - depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). - psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. the target symptoms of psychoneurosis that

United States - English - NLM (National Library of Medicine)

watson laboratories inc. - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - tablet - 7.5 mg - carefully consider the potential benefits and risks of meloxicam and other treatment options before deciding to use meloxicam. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (seewarnings ). meloxicam is indicated for relief of the signs and symptoms of osteoarthritis. meloxicam is contraindicated in patients with known hypersensitivity to meloxicam. meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (seewarnings, anaphylactoid reactions , andprecautions, pre-existing asthma ). meloxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (seewarnings ).

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - tablet - 50 mg - trazodone hydrochloride is indicated for the treatment of depression. the efficacy of trazodone has been demonstrated in both inpatient and out-patient settings and for depressed patients with and without prominent anxiety. the depressive illness of patients studied corresponds to the major depressive episode criteria of the american psychiatric association’s diagnostic and statistical manual, iii.a major depressive episode implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. this product is contraindicated in patients hypersensitive to trazodone.

United States - English - NLM (National Library of Medicine)

watson laboratories inc. - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - tablet - hypertension enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. heart failure enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology,heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction <35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmac

United States - English - NLM (National Library of Medicine)

watson laboratories, inc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - tablet - 10 mg - citalopram hbr is indicated for the treatment of depression. the efficacy of citalopram hbr in the treatment of depression was established in 4-6 week controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficacy of citalopram in mainta

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - tablet - 5 mg - 1. endocrine disorders. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases. during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus acute rheumatic carditis systemic dermatomyositis (polymyosit

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tablet - 50 mg - tramadol hydrochloride tablets are indicated for the management of moderate to moderately severe pain in adults. tramadol hydrochloride should not be administered to patients who have previously demonstrated hypersensitivity to tramadol, any other component of this product or opioids. tramadol hydrochloride is contraindicated in any situation where opioids are contraindicated, including acute intoxication with any of the following: alcohol, hypnotics, narcotics, centrally acting analgesics, opioids or psychotropic drugs. tramadol hydrochloride may worsen central nervous system and respiratory depression in these patients. tramadol hydrochloride may induce psychic and physical dependence of the morphine-type (μ-opioid). (seewarnings . ) dependence and abuse, including drug-seeking behavior and taking illicit actions to obtain the drug are not limited to those patients with prior history of opioid dependence. the risk in patients with substance abuse has been observed to be higher. tramadol hydrochloride is ass

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - tablet, extended release - 324 mg - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (seedosage and administration ), then quinidine gluconate should be discontinued. chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. in patients

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - nandrolone decanoate (unii: h45187t098) (nandrolone - unii:6pg9vr430d) - injection - nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. surgically induced anephric patients have been reported to be less responsive. - male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate. male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate. - carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. - pregnancy, because of masculinization of the fetus. pregnancy, because of masculinization of the fetus. - nephrosis or the nephrotic phase of nephritis. nephrosis or the nephrotic phase of nephritis. nandrolone decanoate injection is classified as a schedule iii controlled substance under the anabolic steroids control act of